December 16, 2024
MPE at ASH 2024: key research and expert insights on myeloma
MPE at ASH 2024: key research and expert insights on myeloma
Latest news
At the 2024 American Society of Hematology (ASH) Annual Meeting, Myeloma Patients Europe (MPE) interviewed experts about the most interesting studies and abstracts in myeloma and AL amyloidosis research that were presented during the conference.
Our series of interviews highlights key findings and their impact on patient care:
🎥 Dr. Laurent Garderet discusses the IFM2017-03 phase 3 trial analysing a dexamethasone-sparing regimen with daratumumab and lenalidomide for frail patients with newly diagnosed myeloma. He highlights significant improvements in patients’ progression-free survival (PFS) and quality of life.
🎥 Dr. Ciara Freeman breaks down the iMMagine-1 phase 2 clinical trial, focusing on CAR-T cell therapy, anitocabtagene autoleucel, and its potential to transform outcomes for myeloma patients.
🎥 Dr. Meletios Dimopoulos and Dr. Albert Oriol summarise the Aquila study, which shows promising results for daratumumab monotherapy in patients with high-risk smouldering myeloma.
🎥 Dr. Anna Fleischer discusses her abstract on balancing treatment intervals and quality of life in myeloma patients, offering unique patient perspectives and recommendations.
You can also watch the MPE ASH 2024 highlights webinar recording here.